Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Meta Expands AI Training With Employee Activity Tracking Tools 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
CAMBRIDGE, Mass., Feb. 24, 2016 -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that it will present at the Canaccord Genuity Musculoskeletal Conference in Orlando, FL on Tuesday, March 1, 2016; Vericel CFO Gerard Michel will present a corporate update at 3:30PM EST with a live webcast at http://wsw.com/webcast/canaccord22/vcel.
About Vericel Corporation
Vericel Corporation is a leader in developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the U.S.: Carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area. Vericel is also developing MACI™, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. For more information, please visit the company’s website at www.vcel.com.
CONTACT: Chad Rubin The Trout Group [email protected] (646) 378-2947 or Lee Stern The Trout Group [email protected] (646) 378-2922
